Evidence map›Paper›PMID 35620021›Full record

Trial reportClinical interventions in aging2022

The Median Effective Dose and Bispectral Index of Remimazolam Tosilate for Anesthesia Induction in Elderly Patients: An Up-and-Down Sequential Allocation Trial.

Miao Liu, Yuan Sun, Lingxue Zhou, Kunpeng Feng, Tianlong Wang, Xuexin Feng

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical interventions in aging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. [THRIVE combined with i-gel laryngeal mask for prolonging apneic oxygenation time in retrograde intrarenal surgery].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023
    Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Miao LiuDepartment of Anesthesiology, Capital Medical University Xuanwu Hospital, Beijing, People's Republic of China.
Yuan SunDepartment of Anesthesiology, Capital Medical University Xuanwu Hospital, Beijing, People's Republic of China.
Lingxue ZhouDepartment of Anesthesiology, Capital Medical University Xuanwu Hospital, Beijing, People's Republic of China.
Kunpeng FengDepartment of Anesthesiology, Capital Medical University Xuanwu Hospital, Beijing, People's Republic of China.
Tianlong WangDepartment of Anesthesiology, Capital Medical University Xuanwu Hospital, Beijing, People's Republic of China.
Xuexin FengDepartment of Anesthesiology, Capital Medical University Xuanwu Hospital, Beijing, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Remimazolam is a new type of ultrashort benzodiazepine drug with an unclear optimal dose for general anesthesia induction in elderly patients aged >60 years. Therefore, this study aimed to determine the effective dose of remimazolam tosilate induction and explore its correlation with the bispectral index (BIS). Patients and Methods: A total of 42 elderly patients were divided into two age groups: 60-69 (group A) and 70-85 (group B) years. An initial dose of 0.1mg/kg(Group A) and 0.05 mg/kg(Group B) remimazolam tosilate was administered, and the Modified Observer's Assessment of Alertness/Sedation scale was used to assess adequate responses. The dose was calculated using the up-and-down allocation technique based on the previous response. The sequential formula and probit regression model were used to calculate ED50 and BIS50. ED95 was determined using the probit regression model. Results: The ED50 of remimazolam tosilate for anesthesia induction were 0.088 mg/kg (95% confidence interval [CI] 0.071-0.108) and 0.061 mg/kg (95% CI 0.053-0.069) in groups A and B, respectively. ED95 was 0.118 mg/kg (95% CI 0.103-0.649) and 0.090 mg/kg (95% CI 0.075-0.199) in groups A and B, respectively. The remimazolam tosilate administration could decrease BIS. BIS50 was 86.0 (95% CI 83.7-88.6) and 85.4 (95% CI 84.1-86.8) in groups A and B, respectively. Conclusion: During the induction process, patients' consciousness should be observed. The dose of remimazolam tosilate could be chosen after careful consideration of individual variations.

Indexed as

BenzodiazepinesHypnotics and SedativesAgedAged, 80 and overAnesthesia, GeneralDouble-Blind MethodHumansMiddle AgedBenzodiazepinesHypnotics and Sedativesremimazolamanesthesia inductiongeriatricremimazolamup-and-down sequential allocation

Identifiers

PMID35620021
PMCPMC9129099

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.